GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.

One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”

New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary. 

Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.

In fact, more than 55% of all PCI cases in 2022 were performed using radial access. Cardiologists are sure to be keeping a close eye on this trend as time goes on.

Staying vaccinated as recommended by doctors can help patients limit their risk of adverse cardiovascular events, according to a new consensus statement published in European Heart Journal.

Even TAVR patients not treated using transfemoral access can typically go home the very next day.